SecBot SecBot

IONS drug pipeline

IONIS PHARMACEUTICALS INC · 6 rated drugs
$29.06
+6.4% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.2%
1-day, median of 23 events
IV rank
No data
No current options data
Rated drugs
6
2 bullish · 1 mixed · 3 neutral
Phase 3 trials
3
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    DAWNZERA
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketRegulatory submission is expected soon — Roche plans to share data with health authorities to seek approval. If filed under standard review, potential approval could come in 2027-2028. The timeline depends on Roche's submission strategy and whether the FDA grants expedited review pathways.

sefaxersen Updated Oct 23

What to watch

The Phase 3 success is a major derisking event, but the stock hasn't rallied, watch for regulatory submission timing from Roche and the week 105 eGFR data, which will determine the full approval path. The stock near its 52-week low with strong analyst support and a deep pipeline (bepirovirsen/HIBSAGO just approved, zilganersen PDUFA passed) creates an asymmetric risk/reward for investors willing to wait for regulatory milestones.

Bull case
  • Phase 3 IMAgINATION study met primary endpoint with a highly significant 43.1% reduction in proteinuria vs placebo (P<0.0001), a strong efficacy signal that positions sefaxersen as potentially best-in-class for IgAN
  • Clean safety profile with no new safety signals, consistent with Phase 2, a key differentiator versus some competitors with boxed warnings
  • Roche is a deep-pocketed partner committed to regulatory submission, providing development and commercialization firepower
Bear case
  • Regulatory approval is not guaranteed, the FDA may require additional data, particularly the week 105 eGFR data showing long-term kidney function benefit, before approving
  • Competition from approved IgAN therapies like Tarpeyo (budesonide) and Filspari (sparsentan) could limit market share and pricing power
  • Stock is trading near its 52-week low (~$42.93 vs 52-week high of $86.74), suggesting the market may have already priced in positive Phase 3 results or has other concerns about Ionis
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and marketed. First approval (FCS) in Dec 2024, second (sHTG) in June 2026 with commercial launch planned for July 2026.

TRYNGOLZA olezarsen Updated Jul 9

What to watch

The sHTG approval binary just resolved positively on June 24, 2026. The investor focus now shifts to execution: watch Q3 2026 TRYNGOLZA sales for sHTG launch trajectory, payer reimbursement decisions at the $40K annual price point, and whether Arrowhead's competing plozasiran (Redemplo) threatens market share. A separate bearish overhang is the July 9 eplontersen Phase 3 failure in ATTR-CM, which pressured IONS stock, this is a separate pipeline setback, not a TRYNGOLZA-specific issue.

Bull case
  • First and only FDA-approved treatment for sHTG that also reduces acute pancreatitis risk, a strong differentiation vs existing therapies (fibrates, fish oil, statins) that don't have pancreatitis reduction data.
  • Massive addressable market: >3 million U.S. patients with sHTG (TG≥500 mg/dL), including ~1 million high-risk patients, vs ~3,000-5,000 for the initial FCS indication.
  • Peak sales guidance raised twice in 6 months: from >$1B to >$2B (Jan 2026) to >$3B (Apr 2026), reflecting growing confidence from HCP demand and payer research. 2025 first-year sales of $105-108M already beat expectations for FCS alone.
Bear case
  • The 93% price cut from $595K to $40K massively reduces per-patient revenue, the $3B peak sales estimate relies on treating tens of thousands of patients, a very aggressive assumption for a specialty injectable drug in a disease where many patients are managed with diet and generic therapies.
  • Competition looms: Arrowhead Pharmaceuticals' plozasiran (Redemplo), a GalNAc-conjugated siRNA targeting the same apoC-III pathway, is in late-stage development and could launch as a direct competitor with a potentially differentiated dosing profile.
  • Commercial execution risk: sHTG is Ionis's first independent large-market launch. The company has historically been a research/commercial-partner firm (partners like Biogen, Novartis, AstraZeneca handled sales). Building a primary-care-capable sales force is a new challenge.
● neutral
Impact
PhasePhase 3 (completed)
Time to marketOtsuka has not yet announced a formal regulatory submission. If filed under an expedited pathway (breakthrough therapy or priority review), FDA action could come 6-10 months after submission, potentially in late 2027 or early 2028.

ulefnersen Updated Nov 10

What to watch

The Phase 3 binary is past (positive, September 2026). The next catalyst is Otsuka's regulatory submission to the FDA, which Otsuka said it would pursue with urgency but no formal filing or PDUFA date has been announced as of November 10, 2026. Watch for Otsuka to announce an NDA/BLA submission and potential priority review or breakthrough therapy designation. For Ionis, ulefnersen is a partnered royalty asset; the stock's near-term direction is more driven by Tryngolza commercial execution.

Bull case
  • The Phase 3 FUSION trial met its primary endpoint with high statistical significance (p=0.0005), making ulefnersen the first-ever placebo-controlled study to show benefit in FUS-ALS and only the second disease-modifying therapy for any form of ALS.
  • Otsuka has established a global Early Access Program, signaling confidence in the data and a commitment to rapid patient access ahead of formal approval.
  • Ionis licensed ulefnersen to Otsuka in 2024 and is eligible for regulatory and sales milestone payments plus tiered royalties (reportedly 20-30% range based on similar Ionis-Otsuka deals), providing upside with no commercial expense.
Bear case
  • FUS-ALS is an ultra-rare indication (likely a few hundred to low thousands of patients globally), capping peak sales potential and making the drug a modest royalty earner for Ionis rather than a blockbuster.
  • Ionis does not control the regulatory or commercial timeline; Otsuka leads all discussions with the FDA and other health authorities, so Ionis shareholders have no direct line of sight on submission timing.
  • Ionis stock fell 21% on November 9, 2026 after Q3 earnings revealed Tryngolza launch struggles and a pushed-back cash-flow positivity target, showing that ulefnersen's positive data has not insulated the stock from other pipeline disappointments.
● neutral
Impact
PhaseApproved (FDA, NDA 219407)
Time to marketAlready approved and on the U.S. market — FDA approval Aug 21, 2025 (NDA 219407, New Molecular Entity).

DAWNZERA donidalorsen Updated Aug 1

What to watch

DAWNZERA itself is not a near-term trading catalyst, the binary event (FDA approval) already happened in Aug 2025 and did not move IONS. For a non-medical investor, Dawnzera matters as part of Ionis' commercial portfolio story; the next hard price drivers for IONS stock are the zilganersen PDUFA (Sep 22, 2026) and bepirovirsen PDUFA (Oct 26, 2026). Watch quarterly earnings disclosures (10-Q filed Jul 29, 2026) for Dawnzera launch metrics, and note the rising FINRA short position (~12.13% of est. shares outstanding at the 7/15/2026 settlement) and July insider sales as sentiment headwinds.

Bull case
  • Already approved and revenue-generating: FDA approval Aug 21, 2025 as a Type 1 New Molecular Entity, donidalorsen (OPENFDA catalyst record, NDA 219407), removing the approval binary risk.
  • Self-administered autoinjector presentation ('DAWNZERA (AUTOINJECTOR)') positions it as a convenient home-use prophylactic in a defined rare-disease population (Hereditary Angioedema, per the completed NCT04307381 extension study).
  • Company-level support: IONS analyst consensus is 16 Buy + 11 Strong Buy vs 6 Hold and 0 Sell, with a mean price target of $90.8 vs ~$51.6 price (≈73.8% implied upside) as of Jul 31, 2026.
Bear case
  • The approval itself did not move the stock: local catalyst-outcome data shows IONS fell -0.28% (1-day) and -1.49% (5-day) around the Aug 21, 2025 approval, the event was largely priced in.
  • No DAWNZERA-specific dated binary in the next ~12 months (no pending PDUFA/sNDA for this drug in local FDA catalyst data), so near-term IONS upside depends on other programs, not this product.
  • Rising bearish positioning at the company level: FINRA short interest grew +15.02% at the 7/15/2026 settlement to ~20.0M shares, ~12.13% of estimated shares outstanding (FINRA estimate, not float; days to cover 3.68), and weighted short-volume ratio was ~0.57 over the last 40 sessions.
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved (December 2023) for hATTR-PN. ATTR-CM label expansion now appears unlikely after the Phase 3 failure.

eplontersen Updated Jul 9

What to watch

The ATTR-CM expansion (a vastly larger addressable market than hATTR-PN) just failed, removing a major bull thesis for IONS. The approved hATTR-PN business continues generating ~$49M/yr in royalties for Ionis, but the stock's ~20% selloff on July 9 reflects the lost upside. Watch for whether the prespecified monotherapy subgroup (HR 0.71) generates any salvage strategy with regulators, though analysts are skeptical.

Bull case
  • Already FDA-approved and launching commercially for hATTR-PN, $212M in 2025 sales, growing, with new country launches (EU, China), generating predictable royalty revenue for Ionis.
  • Monotherapy subgroup (patients not on TTR stabilizers) showed a nominally significant 29% risk reduction (HR 0.71) on the composite endpoint; this could support a future salvage strategy or targeted trial in treatment-naive ATTR-CM patients.
  • Favorable safety profile consistent across both trials; the only self-administered monthly auto-injector option for ATTRv-PN, offering a convenience advantage over Alnylam's Amvuttra (still physician-administered quarterly) and infused Onpattro.
Bear case
  • CARDIO-TTRansform Phase 3 trial for ATTR-CM, a market many times larger than hATTR-PN, failed its primary endpoint, eliminating the most significant value-driving catalyst and dramatically narrowing the drug's total addressable market.
  • Alnylam's Amvuttra (vutrisiran) is already FDA-approved for both hATTR-PN and ATTR-CM (March 2025) and BridgeBio's Attruby (acoramidis) and Pfizer's Vyndaqel/Vyndamax (tafamidis, >$6B in sales) dominate ATTR-CM, leaving eplontersen competitively disadvantaged without a CM indication.
  • In the CARDIO-TTRansform trial, patients already on TTR stabilizers (likely most patients in real-world practice) derived no apparent benefit from adding eplontersen, muddying any potential combination strategy.
● neutral
Impact
Phaseunknown (not present in SecBot's Phase 2/3 clinical-trial database; no FDA action or catalyst on record)
Time to marketunknown — no phase, trial, or regulatory filing could be verified from available sources this session; if it is an early-stage antisense program, commercialization would be years away

obudanersen Updated Aug 1

What to watch

Do not build an Ionis position on obudanersen, it has essentially no public footprint and no dated catalyst, so there is nothing binary to trade. If you hold IONS for other reasons, the near-term share-price drivers are the zilganersen PDUFA on Sept 22, 2026 and the bepirovirsen PDUFA on Oct 26, 2026, and any future Ionis pipeline update that finally reveals obudanersen's indication and phase (its target/indication could not be verified from any source this session).

Bull case
  • Obudanersen is a named, active pipeline program at Ionis, it appears in the drug list extracted from the company's Q2 2026 earnings 8-K analysis, alongside development code ION775 (filing analysis, filed 2026-07-29).
  • Ionis has the resources to carry early programs: the same earnings analysis reports ~$2.1B in cash and short-term investments as of June 30, 2026 and maintained FY2026 revenue guidance of $875-900M.
  • Company-level analyst sentiment is positive regardless of this program: consensus shows 16 Buy + 11 Strong Buy vs 6 Hold and 0 Sell, with a mean price target of $90.8 vs the $51.77 close.
Bear case
  • Zero verifiable footprint: no FDA action, catalyst, clinical-trial record, press release, or news mention of obudanersen/ION775 was found in any tool result this session, consistent with a very early/preclinical-stage asset that carries high attrition risk and is years from market.
  • No dated catalyst: with no scheduled readout, PDUFA, or filing for obudanersen, there is no share-price binary to underwrite; it cannot move the stock on its own.
  • Ionis pipeline execution risk is demonstrably live: the CARDIO-TTRansform Phase 3 miss for eplontersen (with AstraZeneca) cut IONS shares ~23% on July 9, 2026 and drew a Levi & Korsinsky investigation notice, a reminder that Ionis clinical assets fail, and early-stage ones fail most often.

Other drugs in filings and trials

no drug report yet
  • bepirovirsen Last: Priority review · Oct 26, 2026
  • Hibsago Last: Approval · Oct 20, 2026
  • zilganersen Last: PDUFA decision · Sep 22, 2026
  • ZANVASTRO Last: Approval · Sep 3, 2026
  • Salanersen Last: Breakthrough designation · Aug 12, 2026
  • SPINRAZA Last: PDUFA decision · Apr 3, 2026
  • ION363 1 trial
  • sapablursen 1 trial

Past FDA events & how the stock moved

23 events
DateDrugEvent1 day5 days
Oct 26, 2026bepirovirsenPriority review+2.4%—
Oct 26, 2026bepirovirsenPDUFA decision+2.4%—
Oct 26, 2026bepirovirsenBreakthrough designation+2.4%—
Oct 20, 2026HibsagoApproval−0.3%—
Oct 20, 2026HibsagoPriority review−0.3%—
Oct 20, 2026HibsagoBreakthrough designation−0.3%—
Sep 22, 2026zilganersenPDUFA decision−2.2%+2.2%
Sep 22, 2026zilganersenPriority review−2.2%+2.2%
Sep 3, 2026ZANVASTROApproval−5.3%−11.6%
Aug 12, 2026SalanersenBreakthrough designation+0.8%+9.7%
Aug 6, 2026SalanersenBreakthrough designation+4.4%+3.1%
Jul 30, 2026SalanersenBreakthrough designation−4.2%+0.8%
Jul 1, 2026zilganersenNDA filed+3.2%−18.9%
Jun 30, 2026TRYNGOLZAPriority review−1.9%+4.7%
Jun 30, 2026TRYNGOLZAPDUFA decision−1.9%+4.7%
Jun 24, 2026TRYNGOLZAApproval+3.1%+4.2%
Apr 29, 2026TRYNGOLZAPriority review+4.2%+7.1%
Apr 29, 2026bepirovirsenBreakthrough designation+4.2%+7.1%
Apr 3, 2026SPINRAZAPDUFA decision−0.6%+0.5%
Jan 1, 2026SalanersenBreakthrough designation+0.7%+3.1%
Dec 31, 2025TRYNGOLZANDA filed+0.9%+3.3%
Aug 21, 2025DAWNZERAApproval−0.3%−0.4%
Dec 19, 2024TRYNGOLZAApproval−1.7%−0.9%

Clinical trials

6 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
DAWNZERAA Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)Phase 3Active not recruiting154Dec 2026
ION363FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)Phase 3Active not recruiting89Jun 2026
eplontersenCARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Phase 3Completed1,438Mar 25, 2026
sapablursenA Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraPhase 2Completed50Jun 26, 2025
DAWNZERAAn Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaPhase 2Completed · results20Jan 24, 2025
TRYNGOLZAA Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaPhase 2Completed · results154Mar 22, 2023